Mindfulness-Oriented Recovery Enhancement For Chronic Pain and Prescription Opioid Misuse in Primary Care
| Status: | Recruiting |
|---|---|
| Conditions: | Chronic Pain, Chronic Pain |
| Therapuetic Areas: | Musculoskeletal |
| Healthy: | No |
| Age Range: | 18 - 100 |
| Updated: | 2/10/2018 |
| Start Date: | January 2016 |
| End Date: | October 2021 |
| Contact: | Eric Garland, PhD |
| Email: | eric.garland@socwk.utah.edu |
The central aim of this study is to test the efficacy of Mindfulness-Oriented Recovery
Enhancement (MORE), an intervention designed to disrupt the risk chain leading from chronic
pain to prescription opioid misuse and addiction. The investigators plan to conduct a full
scale clinical trial to determine whether MORE (relative to a support group control
condition) can reduce symptoms of chronic pain and opioid misuse among patients who are
receiving pain management in primary care via long-term opioid analgesic therapy.
Enhancement (MORE), an intervention designed to disrupt the risk chain leading from chronic
pain to prescription opioid misuse and addiction. The investigators plan to conduct a full
scale clinical trial to determine whether MORE (relative to a support group control
condition) can reduce symptoms of chronic pain and opioid misuse among patients who are
receiving pain management in primary care via long-term opioid analgesic therapy.
Inclusion Criteria:
- Age 18-60+
- Current back pain diagnosis as determined from ICD-9 codes in claims data (including
but not limited to ICD-9 diagnoses 724.x, or 847.x) or current chronic pain diagnosis
determined by physician assessment (including but not limited to ICD-9 diagnoses
338.0, 338.21, 338.22, 338.28, 338.29, 338.4)
- Current use of prescription opioid agonist or mixed agonist-antagonist analgesics for
>90 days, and evidence of opioid misuse as indicated by the Current Opioid Misuse
Measure
- Willingness to participate in study interventions and assessments
Exclusion Criteria:
- Prior experience with Mindfulness-Based Stress Reduction, Mindfulness-Based Cognitive
Therapy, or Mindfulness-Based Relapse Prevention
- Active suicidality, schizophrenia, psychotic disorder, and/or substance dependence
(other than opioid dependence)
- Presence of clinically unstable systemic illness judged to interfere with treatment
We found this trial at
1
site
Click here to add this to my saved trials
